Menu Search
Equities

Swedish Orphan Biovitrum AB (publ)

SOBI:STO

Swedish Orphan Biovitrum AB (publ)

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)290.00
  • Today's Change-0.600 / -0.21%
  • Shares traded708.73k
  • 1 Year change+20.23%
  • Beta0.1581
Data delayed at least 15 minutes, as of Nov 22 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform7
Hold4
Sell1
Strong Sell0

Share price forecast in SEK

The 11 analysts offering 12 month price targets for Swedish Orphan Biovitrum AB (publ) have a median target of 370.00, with a high estimate of 550.00 and a low estimate of 275.00. The median estimate represents a 27.59% increase from the last price of 290.00.
High89.7%550.00
Med27.6%370.00
Low-5.2%275.00

Earnings history & estimates in SEK

On Oct 24, 2024, Swedish Orphan Biovitrum AB (publ) reported 3rd quarter 2024 earnings of 4.31 per share. This result exceeded the 2.36 consensus of the 4 analysts covering the company and exceeded last year's 3rd quarter results by 4.01.
The next earnings announcement is expected on Feb 06, 2025.
Average growth rate+344.69%
Swedish Orphan Biovitrum AB (publ) reported annual 2023 earnings of 8.55 per share on Feb 08, 2024.
Average growth rate-5.64%
More ▼

Revenue history & estimates in SEK

Swedish Orphan Biovitrum AB (publ) had 3rd quarter 2024 revenues of 6.89bn. This bettered the 5.99bn consensus of the 8 analysts covering the company. This was 31.59% above the prior year's 3rd quarter results.
Average growth rate+9.38%
Swedish Orphan Biovitrum AB (publ) had revenues for the full year 2023 of 22.12bn. This was 17.74% above the prior year's results.
Average growth rate+11.90%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.